- Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q3 GAAP EPS of -$0.62 misses by $0.10 .
- Revenue of $4.02M (+32.7% Y/Y) misses by $0.24M .
- $121.0 million in cash, cash equivalents, and total investments as of September 30, 2022 expected to fund planned operations through 2024
-
Cash, cash equivalents, and total investments as of September 30, 2022 totaled $121.0 million compared to $106.1 million as of December 31, 2021.
-
As of September 30, 2022, the company had 44.0 million common shares outstanding.
-
Cost of sales was $1.2 million for third quarter 2022 as compared to $0.3 million for the same period in 2021.
For further details see:
Eiger BioPharmaceuticals GAAP EPS of -$0.62 misses by $0.10, revenue of $4.02M misses by $0.24M